Finally a drug that shows cognitive improvement

Maxxou

For everyone out there who has a relative with moderate AD, I encourage you to apply for the Simufilam trials. Different caregivers (doctor and lawyer) give the same testimony about their relative improving thanks to the drug called Simufilam.

https://www.youtube.com/watch?v=7VcIYyeUey8 

https://www.youtube.com/watch?v=QIrb7j09R50

 
More than 100 sites are participating in the P3 trials. 

https://rethink-alz.com/ 

  

Larrytherunner

Cassava Sciences announced in February that the FDA may put their trials on hold. Other sources indicate that they are misrepresenting their research. If you own stock in this company, it may be a good time to sell.

https://www.nytimes.com/2022/04/18/health/alzheimers-cassava-simufilam.html

Lane Simonian

This is one of the more divisive drugs in the history of Alzheimer's disease.  Companies often list the possibility of the FDA putting drugs on clinical hold in their financial statements as a hypothetical situation, but Cassava Sciences disclaimer seemed rather defensive.  Maybe that is because it has been subject to all sorts of allegations from manipulating Western blots, to removing an outlier to make a failed drug trial look successful, to manipulating cognitive test numbers.  I think the investigations into the company are going to produce mixed results.

https://www.cassavasciences.com/node/15831/html p.40.

I don't think the company has the right mechanism of action because when it is stripped down it is still an anti-amyloid drug (restoring filamin A to its original form in order to reduce amyloid binding to various receptor).  There are other mechanisms of action, though, that potentially explain simufilam's improvements in cognitive function at one year.

In small, open label trials, Anavex 2-73 (blarcamesine) and panax ginseng/Korean red ginseng have produced better results than simufilam at one year.  If Cassava Sciences is able to replicate its open label trial in phase 3 clinical trials than it will be better than the current standard of care, but probably not the best treatment for Alzheimer's disease ever.

Maxxou

You should be ashamed to speak about investment... We are talking about a disease not a stock. Furthermore you are lying, they never said that FDA may put their trial on hold. It's just a legal statment that every other biotech has to put in their presentations. The FDA ask them to prolong their OL study just a week ago... DOesn't seem to hold the trials.
Oh and your article is the very well known short attack on the company and had been debunked by the CEO. I'm not an investor but you look like a short seller. The simufilam trials are the best chance people with AD have right now.